Atlas FDA

Predicate Research Report · generated 2026-08-22 · Print / save as PDF · Save to account

Carmel Pharma Ab. — Predicate Candidate Screening

7 FDA 510(k) clearances under this manufacturer; the 50 most recent screened below.

29 daysmedian FDA review time
99 days90th percentile
7clearances measured
K-numberDeviceApplicantDecidedReview daysRecalls (K-match)
K110023INFUSION ADAPTER C100Carmel Pharma Ab.2011-04-12990
K092782INJECTOR LUER, MODEL N34, INJECTOR LUER LOCK, MODEL N35, INJCarmel Pharma Ab.2009-12-07880
K090634PHASEAL PROTECTOR P14, P21, P28 AND P50Carmel Pharma Ab.2009-03-23140
K060866PHASEAL - CLOSED SYSTEM FOR THE PREPARATION AND ADMINISTRATICarmel Pharma Ab.2006-04-28290
K023747PHASEALCarmel Pharma Ab.2002-11-1570
K001368PROTECTOR 21, PROTECTOR 50, PROTECTOR 14, INJECTOR LUER LOCKCarmel Pharma Ab.2000-05-12114
K980381PHASEAL, CLOSED SYSTEM FORHANDLING OF PARENTERAL DRUGS, ADDICarmel Pharma Ab.1998-03-03290

Methodology

Recall counts reflect FDA recall records explicitly referencing each K-number; FDA links recalls to K-numbers inconsistently, so 0 means "none found in FDA records," not "never recalled." Data: FDA openFDA, refreshed weekly. Verify decisions of consequence against the primary source. Full candidate set and CSV export: atlasbyauro.com.

Prepared with Atlas

Predicate research, review-time statistics and recall monitoring for 510(k) teams — atlasbyauro.com/fda